Mico Biomed

MiCo BioMed, founded in 2004, is focused on developing a next-generation diagnostics and life sciences platform using innovative microfluidics for immunoassays. MiCo BioMed’s market-proven Optimiser™ technology integrates the power of microfluidics into easy-to-use high- medium- and low-throughput platforms, as well as allows for manual testing using the same assay disposables. Over 70 assays have been developed using the Optimiser™ technology platform, proving the robustness and universal nature of this platform. MiCo BioMed invites diagnostic and life science companies to learn about our Optimiser™ technology. Our proven Optimiser™ microfluidic platform is already commercially offered to the life science market. It provides users unheard-of enhancements in automation workflow and improved assay throughput. ELISAs use sample sizes of less than a drop of blood (3 to 5 uL). Optimiser™ technology allows users to tune their assay, typically with no change in their own or commercially available reagents.